77 citations
,
June 2017 in “Advances in Therapy” New treatments for Alopecia Areata, like JAK inhibitors, show promise for hair regrowth and are likely to change future treatment approaches.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
May 2025 in “Galen Medical Journal” Psoriasis affects 2-3% of the global population and involves immune dysregulation, keratinocyte dysfunction, and genetic/epigenetic changes, with comorbidities like psoriatic arthritis and cardiovascular disease. Recent advances using single-cell RNA sequencing and transcriptomics have identified key mechanisms such as GSDME-mediated pyroptosis and IL-23/IL-17 axis activation. Targeted therapies, including IL-17 inhibitors like secukinumab and IL-23 inhibitors like risankizumab, show promise, while novel treatments like hyperforin and Deu@Cal microneedles are in early stages. Challenges include adverse events, treatment resistance, and personalization gaps. Future efforts focus on multi-omics integration and combination therapies to enhance precision medicine in psoriasis management.
3 citations
,
June 2025 in “Archives of Dermatological Research” Biologics and JAK inhibitors may improve treatment for scarring alopecias.
March 2026 in “Biomedicines” New treatments like biologics and JAK inhibitors show promise for severe scalp inflammation when traditional methods fail.